Good
Mostly Aligned
Patient Risk:
Low
Summary
The response’s core medical claim about indication (positive control for wheal-flare in allergy skin testing) and key administration timing (read at 15 minutes for scratch/prick/puncture) is supported by the label text included in the prompt. However, the overall audit is under-validated because it asserts “supported” for the main claim without fully confirming complete labeling identity/section numbering and without evaluating other label elements (contraindications, warnings/precautions, interactions, adverse reactions, populations, etc.) against the AI claims.
Category Scores
Accurate Statements
Positive Skin Test Control – Histamine is indicated as an adjunct in allergy skin testing as a positive control to test the wheal-flare response of the skin for evaluation of responses to allergenic extracts.
SECTION 1 — INDICATIONS AND USAGE: “indicated as an adjunct in allergy skin test… as a positive control to test wheal-flare response… for evaluation of skin test response to allergenic extracts.”
For scratch, prick or puncture testing, the skin test should be read in 15 minutes.
SECTION 2 — DOSAGE AND ADMINISTRATION: “Scratch, Prick or Puncture test… The Scratch, Prick or Puncture test should be read in 15 minutes.”
Unsupported Statements
“Supported: yes” and a “supported” determination are asserted for label adherence based on the provided information, despite not verifying full FDA-approved label identity and completeness.
The response’s support judgment is not fully auditable from the prompt because no label identifier/NDA/BLA and complete label text were provided; section numbering/wording beyond the excerpt cannot be independently verified. (This is an audit-coverage limitation rather than a contradiction to the included excerpts.)
Contradictions
Important Omissions
No evaluation was provided for other label elements that could affect safety or correct use (e.g., contraindications, precautions such as availability of epinephrine/tourniquet and observation period, boxed warnings if any, interaction discontinuation timelines, adverse reactions management).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response contains no direct dosing beyond the labeled read-time and does not provide safety-misleading contraindication/warning statements; main label-aligned claim concerns intended use and timing. Limited audit scope reduces confidence but does not introduce a clear safety contradiction.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Label-adherence determination is not fully auditable because the response asserts broader “supported” status without complete label identity/coverage across all safety-critical sections.
Suggested Improvement
Provide the exact FDA label identifier and evaluate all label-relevant elements (contraindications, warnings/precautions including epinephrine/tourniquet and observation time, interaction discontinuation timelines, adverse reactions/systemic reaction management, and any population-specific statements) against the AI’s claims, or limit conclusions to only the excerpts verified.